AveXis — FY2016 Earnings Presentation
18 slides from AveXis's earnings presentation, Mar 16, 2017
Slide 1: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical studies and clinical trials for AVXS-101, including statements regarding the timing of initiation of studies or trials and related preparato
Slide 2: Our Strategy
Our Strategy 3 Build pipeline of gene therapy treatments beyond SMA Expand development of AVXS-101 into SMA Type 2 Establish foundational presence in SMA Type 1 Vision: Leader in rare and life-threatening neurological genetic diseases Strategic Focus & Investment Time
Slide 3: Overview of SMA
Overview of SMA 4 SMA is a devastating orphan disease that results in motor neuron loss and progressive weakness; it is the most common genetic cause of infant death Incidence: ~1 in 10,000 live births Caused by reduced SMN (survival motor neuron) protein levels from loss of/defective SMN1 gene SMA
Slide 4: SMA Types: A Devastating Disease
SMA Types: A Devastating Disease 5 TYPE 1 TYPE 2 TYPE 3 TYPE 4 SMN2 Copy Number Two Three or Four Three or Four Four to Eight Onset Before 6 Months 6-18 Months Early childhood to early adulthood (juvenile) Adulthood (20s-30s) usually after 30 Incidence per Live Birth Approximately 60% Approximately
Slide 5: Natural History of SMA Type 1
Natural History of SMA Type 1 “floppy baby” syndrome muscle weakness (legs more than arms) poor head control belly breathing bulbar muscle weakness (weak cry, difficulty swallowing, aspiration) will never sit unsupported loss of motor function: NeuroNEXT -- CHOP INTEND decrease of 10.5 points/yr. PN
Slide 6: AVXS-101 Targets the Primary SMN Gene
AVXS-101 Targets the Primary SMN Gene 7 NORMAL INDIVIDUAL SMA-AFFLICTED INDIVIDUAL SMA-AFFLICTED INDIVIDUAL TREATED WITH AVXS-101 SMN Genes SMN Protein SMN1 Primary SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up AVXS-101 Primary Functional SMN Protein No
Slide 7: Our Solution: AVXS-101 An Innovative Treatment Approach for SMA
Our Solution: AVXS-101 An Innovative Treatment Approach for SMA 8 scAAV ITR Continuous Promoter Human SMN Transgene scAAV ITR KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver across the blood brain barrier (BBB) and into the spinal cord - Avoids the need for intrathecal delive
Slide 8: Children with SMA Type 1 Do Not Reach Any Major Motor Milestones
Children with SMA Type 1 Do Not Reach Any Major Motor Milestones Retrospective Study from large multi-center datasets (US and EU) Patients (n=33) have genetically confirmed homozygous deletion of exon 7 in SMN1 gene; categorized according to Dubowitz’s decimal classification (confirmation of SMN1 st
Slide 9: Clinical Study Closeout – January 20, 2017
Clinical Study Closeout – January 20, 2017 10 TRIAL OVERVIEW Route of Administration One-time intravenous infusion through peripheral limb vein Prednisolone 1 mg/kg 1 day Pre-GT Trial Design Open-label, dose-escalation Principal Investigator Jerry R. Mendell, M.D. AVXS-101 PHASE 1 TRIAL OVERVIEW – S
Slide 10: Event-Free Survival Data – January 20, 2017
Event-Free Survival Data – January 20, 2017 * A month is defined as 30 days Cohort 1 6.7E13 vg/kg Cohort 2 2.0E14 vg/kg PNCR (Finkel) 2014 Natural History Study: 75% event-free 50% event-free 25% event-free 8% event-free 11 Age at Last Follow-up Cohort 1*: 30.8 months (median) 30.4 months (mean) Coh
Slide 11: CHOP INTEND vs. Age – January 20, 2017
CHOP INTEND vs. Age – January 20, 2017 12 COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age (months): 30.8 [median], 30.4 [mean] Mean CHOP INTEND Increase: 7.7 points COHORT 2 (n=12) Baseline Age (months): 3.1 [median], 3.4 [mean] Current Age (months): 20.2 [median], 20.7 [m
Slide 12: Safety Data – January 20, 2017
Safety Data – January 20, 2017 SAFETY AND TOLERABILITY OBSERVATIONS No new treatment-related SAEs or AEs observed As previously reported, a total of 5 treatment-related AEs in 4 patients have been reported following monitoring and source verification Treatment-related SAEs and AEs were clinically as
Slide 13: Children with SMA Type 1 Never Sit Unassisted
Children with SMA Type 1 Never Sit Unassisted 14 Disease Characteristics Disease onset <6 months Hypotonia and weakness Bulbar muscle weakness Difficulty breathing and swallowing Inexorable progression to nutritional failure Inexorable progression to respiratory failure Developmental Milestone Progn
Slide 14: Motor Milestone Achievement Assessed and Adjudicated by Independent External Reviewer
Motor Milestone Achievement Assessed and Adjudicated by Independent External Reviewer – January 20, 2017 15 Cohort 2 2.0e14 vg/kg Age at GT (mos) Motor Milestone Achievement Brings hand to mouth Head control Partial Rolla Rollb Sitting with assistance Sitting Unassisted > 5 secondsc > 10 secondsd >
Slide 15: Financial Position
Financial Position (dollars in millions) 16 Cash and cash equivalents of $240.4 million as of December 31, 2016 Three months ended 12/31/16 Three months ended 12/31/15 R&D Expense $18.3 $8.7 G&A Expense $7.2 $4.4 Net Loss $25.4 $13.2
Slide 16: Company Milestones
Company Milestones 17 Type 1 Program Type 2 Program 2017 Manufacturing Q2 2017: Initiate SMA Type 1 pivotal trial in U.S.* Q1 2017: Provide update on EU regulatory pathway and trial design feedback Q2 2017: Anticipated update/minutes from CMC Type B meeting Q1 2017: 13.6 months of data for all patie
Slide 17: Company Milestones
Company Milestones
Slide 18: Thank You
Thank You avelis